LY2886721 is an orally-available, furothiazine-based inhibitor of b-amyloid protein cleaving enzyme (BACE) for the treatment of Alzheimer's disease. [1] It inhibits recombinant hBACE1 with an IC50 of 20 nM. [2] In cellular assays, LY2886721 inhibits Abeta with an IC50 range of 10-19 nM. Oral administration of LY2886721 to PDAPP mice produced dose-dependent reductions in brain Abeta, C99, and sAPPbeta. [2]